Search - tctmd.com

Displaying 21 - 40 of 50

Sort: Relevancy | Date

News Conference News ESC 2020

EVAPORATE: Icosapent Ethyl May Slow Atherosclerosis Progression

Yael L. Maxwell

September 02, 2020

News Daily News

Icosapent Ethyl Could Prevent Thousands of CVD Events if Used as Indicated

Yael L. Maxwell

August 27, 2020

News Daily News

High-Sensitivity Troponin Hones ASCVD Risk in Secondary Prevention

Michael O'Riordan

August 11, 2020

News Conference News SCAI 2020

Icosapent Ethyl Lowers Revasc Rates Across the Board: REDUCE-IT Data

Caitlin E. Cox

May 15, 2020

News Daily News

Different Markers of Dyslipidemia Could Help Fine-tune CVD Prevention

Yael L. Maxwell

April 28, 2020

News Conference News ACC 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

Todd Neale

April 02, 2020

Presentation ACC 2020

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Presenter: Deepak L. Bhatt

March 30, 2020

News Daily News

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

Yael L. Maxwell

December 20, 2019

News Daily News

FDA Approves Icosapent Ethyl for Reducing CVD Events

Michael O'Riordan

December 13, 2019

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

Todd Neale

December 10, 2019

News Daily News

Many ASCVD Patients Skimp on CV Meds Due to Costs: US Survey

Caitlin E. Cox

November 25, 2019

News Conference News AHA 2019

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

Todd Neale

November 18, 2019

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

News Conference News AHA 2019

AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials

Shelley Wood

November 11, 2019

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

News Conference News ESC 2019

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

Yael L. Maxwell

September 06, 2019

News Daily News

New AHA Guidance on Omega-3 Fatty Acids for High Triglycerides

Michael O'Riordan

August 21, 2019

News Daily News

A Boost for Prescription Omega-3s? Not Yet: FDA Panel Set for November

Yael L. Maxwell

August 14, 2019

News Daily News

No Need for Niacin? Meta-analysis Argues the End Is Nigh

Yael L. Maxwell

April 22, 2019

News Conference News ACC 2019

REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events

Yael L. Maxwell

March 22, 2019

Advertisement

EVAPORATE: Icosapent Ethyl May Slow Atherosclerosis Progression

Icosapent Ethyl Could Prevent Thousands of CVD Events if Used as Indicated

High-Sensitivity Troponin Hones ASCVD Risk in Secondary Prevention

Icosapent Ethyl Lowers Revasc Rates Across the Board: REDUCE-IT Data

Different Markers of Dyslipidemia Could Help Fine-tune CVD Prevention

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

FDA Approves Icosapent Ethyl for Reducing CVD Events

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

Many ASCVD Patients Skimp on CV Meds Due to Costs: US Survey

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials

Recurrent Events Common Among Young Patients With CAD

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

New AHA Guidance on Omega-3 Fatty Acids for High Triglycerides

A Boost for Prescription Omega-3s? Not Yet: FDA Panel Set for November

No Need for Niacin? Meta-analysis Argues the End Is Nigh

REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content